|
Mr. Parker is President and CEO of Cequent Pharmaceuticals, Inc. Prior to joining Cequent, Mr. Parker was a General Partner at Ampersand Ventures where he focused on the firm�s Life Sciences activities. He has served as a director of numerous companies including ACLARA Biosciences, Tomah Products, VITEX, Magellan Biosciences, Dynex and Pentose Pharmaceuticals and as Chairman of Alexis, NOVEX, CoPharma, Huntington Laboratories, Protein Ingredient Technologies, Cyclis Pharmaceuticals, Nanodyne, Panacos Pharmaceuticals, AC Tech, Boston Heart Lab and TekCel. Prior to Ampersand, Mr. Parker spent fourteen years at AMAX, Inc. where he was President of Climax Performance Materials Corporation and Corporate Director of Research and Development. He holds B.S. and M.S. degrees from Columbia University. | 